BRAF-activated ARSI suppressed EREG-mediated ferroptosis to promote BRAF V600E (mutant) papillary thyroid carcinoma progression and sorafenib resistance

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, and patients with the BRAF mutation often exhibit aggressive tumor behavior. Here, we identified Arylsulfatase I (ARSI) as a gene whose expression was significantly upregulated in BRAF PTC and was associated with poor progn...

Ausführliche Beschreibung